Slide from Dr Lynn Silver's talk: "Why Novel Antibacterial Discovery is so Hard and what to do about it"
Slides from Prof Chris Downson's SWON Industry Workshop (22-23 Sep) are now available:
warwick.ac.uk/wamic/swon/industry/slides
Talk titles:
INTEGRATE AMR - Opportunities to Collaborate with Warwick
Dr Chandrika Nair, University of Warwick
Why Novel Antibacterial Discovery is so Hard and what to do about it
Dr Lynn Silver, Consultant to Pharmaceutical Industry
MRCT's Centre for Therapeutics Discovery
Dr Andy Meritt, Associate Director Chemistry, Medical Research Council Technology
Dstl Medical Countermeasures for Dangerous Pathogens
Dr Andrew Scott, Defense Science and Technology Laboratory
New Directions in Structural Biology at Diamond
Prof Martin Walsh, Diamond Light Source
Discovering Diverse Chemical Starting Points
Dr Tobias Krojer, Structural Genomic Consortium, University of Oxford
Structure-guided Design in the Discovery of Antimicrobials
Prof Colin Fishwick, University of Leeds
What if there are No New Antibiotics?
Dr Lloyd Czaplewski, Chemical Biology Ventures
Tackling AMR - new ways of working
Dr Ghada Zoubiane, Medical Research Council
AMR Collaborative Grants at the University of Bristol
Dr Matthew Avison, University of Bristol
SWON Alliance Cross Council AMR Collaborative
Prof Chris Dowson, University of Warwick
The SHIELD Consortium
Prof David Dockrell, University of Sheffield
Fragments for drug discovery and chemical biology
Prof Rod Hubbard, University of York
Developing DNA topoisomerases as targets for antibacterial chemotherapy
Prof Tony Maxwell, John Innes Centre
Challenges in developing new antibacterial drugs
Dr Richard Bax, TranScrip Senior Partner
Chemical Evolution of B Lactams to Keep Pace with Bacterial Resistance
Dr Malcolm Page, Former Head of Biology, Basilea Pharmaceutica Ltd